Calydon Capital Trims Stake in Eli Lilly and Company

Hedge fund reduces position in pharmaceutical giant by over 50%

Mar. 16, 2026 at 8:52am

Got story updates? Submit your updates here. ›

Calydon Capital, an investment management firm, has reduced its stake in Eli Lilly and Company (NYSE: LLY) by 52.6% during the third quarter, according to a recent 13F filing with the Securities and Exchange Commission. The firm now owns 2,510 shares of the pharmaceutical company's stock, down from 5,297 shares held previously.

Why it matters

Eli Lilly is one of the largest and most prominent pharmaceutical companies in the world, so changes in institutional ownership of its stock can provide insights into investor sentiment and market trends within the healthcare sector.

The details

According to the 13F filing, Calydon Capital sold 2,787 shares of Eli Lilly during the third quarter. The firm's remaining position in Eli Lilly was valued at $1.915 million at the end of the quarter. The sale represents a significant reduction in Calydon's exposure to Eli Lilly, as the firm previously held a larger stake in the company.

  • Calydon Capital reduced its Eli Lilly position during the 3rd quarter of 2026.

The players

Calydon Capital

An investment management firm that has reduced its stake in pharmaceutical giant Eli Lilly and Company.

Eli Lilly and Company

A global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Calydon Capital's Eli Lilly position could signal a shift in investor sentiment towards the pharmaceutical sector, though more data would be needed to draw broader conclusions. Institutional ownership changes are closely watched by investors and analysts as indicators of market trends.